AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 159 filers reported holding AKERO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $90,695,453 | +179.0% | 1,793,109 | +157.6% | 0.02% | +216.7% |
| Q2 2023 | $32,503,850 | +142.5% | 696,163 | +98.7% | 0.01% | +100.0% |
| Q1 2023 | $13,402,593 | -18.6% | 350,303 | +16.6% | 0.00% | -25.0% |
| Q4 2022 | $16,470,359 | -17.1% | 300,554 | -48.5% | 0.00% | -20.0% |
| Q3 2022 | $19,869,000 | +18469.2% | 583,577 | +5064.4% | 0.01% | – |
| Q2 2022 | $107,000 | -72.6% | 11,300 | -59.0% | 0.00% | – |
| Q1 2022 | $391,000 | -87.2% | 27,553 | -80.9% | 0.00% | – |
| Q4 2021 | $3,046,000 | +60.8% | 143,988 | +69.9% | 0.00% | – |
| Q3 2021 | $1,894,000 | -59.4% | 84,746 | -54.9% | 0.00% | – |
| Q2 2021 | $4,661,000 | -78.4% | 187,860 | -74.8% | 0.00% | -100.0% |
| Q1 2021 | $21,588,000 | +734.2% | 744,125 | +641.6% | 0.00% | – |
| Q4 2020 | $2,588,000 | +24.4% | 100,342 | +48.4% | 0.00% | – |
| Q3 2020 | $2,081,000 | +116.5% | 67,594 | +75.2% | 0.00% | – |
| Q2 2020 | $961,000 | +51.6% | 38,587 | +29.1% | 0.00% | – |
| Q1 2020 | $634,000 | – | 29,894 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |